Haemostasis is the prevention of unwanted blood loss; lean how this process works and is interrupted by blood-clotting and ...

The Global Renal Anemia Market was valued at approximately USD 2.31 Billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.05% over the forecast period from 2024 to 2032 ...

Among patients with myelodysplastic syndromes (MDS), treatment with Reblozyl (luspatercept) resulted in at least 12 weeks of ...

• Acute kidney injury occurs when the kidneys suddenly lose their ability to filter waste from the blood. Erythropoietin-stimulating agents are medicines that are mainly used to treat problems with ...

Erythropoietin (EPO), expressed in red blood progenitor cells, primarily regulates erythropoiesis by binding to its receptor. Besides anemia, recent studies have identified new therapeutic indications ...

For patients with heart failure and reduced or mildly reduced left ventricular ejection fraction, iron deficiency is common ...

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence ...

Therefore, the researchers suggest discontinuing daprodustat to reduce the risk of recurrent ischemic strokes. Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are ...

With a market cap of $2.67 billion, Geron Corporation (GERN) is a small-cap, commercial-stage biopharmaceutical company ...

β-Thalassemia is a genetic disorder characterized by reduced or absent synthesis of the beta chains of hemoglobin, leading to ineffective erythropoiesis and severe anemia. Patients with ...

With FDA approval for imetelstat and solid financials, Geron shows great promise in MDS treatment. Read more on GERN stock ...